In this review, we summarize the work published over the last 2 years using genetic modifications of animals in the field of xenotransplantation. Genetic engineering of the donor has become a powerful tool in xenotransplantation, both for the inactivation of one particular porcine gene and for the addition of human genes with the goal of overcoming xenogeneic barriers. We summarize the work relative to the knockout of the a1,3-galactosyltransferase gene, followed by genetic engineering aimed at reducing the humoral and cellular immune response, complement activation and coagulation. Finally, we report on the genetic modification of pigs to reduce porcine endogenous retrovirus infection risk in the xenogeneic context.
Introduction
Transplantation is currently facing a problem of organ shortage; waiting lists are increasing with some of these patients dying before any proposition of an organ transplant. One solution could be to increase the donor 'reservoir' by using animal organs: that is, xenotransplantation. In the past, non-human primates (NHPs) were used as organ donors for humans , but are no longer considered as potential donors essentially for ethical reasons and for a high risk of endogenous virus transmission to humans. Now, pigs are considered for the future as animals of choice (porcine valves used for years in humans, may not be considered as xenotransplantation as the tissue is devitalized before implantation). In fact, pigs have been identified as potential donors, primarily because of their physiology and anatomy being similar to humans. Moreover, there are no major ethical considerations regarding their use in medicine. Finally, their potential has been increased by the application of the most recent techniques of genetic manipulation: transgenesis, gene transfer through viral vector and cloning through nuclear transfer. However, some significant problems remain regarding their use: immunological barriers and the risk of viral transmission. Manipulations of the pig genome targeting the human or NHP immune responses, coagulation disorders and viral risk are research approaches that will be addressed in this review (Table 1) . Gene inactivation GalT GalT-KO pig Complementarity breeding and SCNT in GalT-KO pig production Nottle et al. 4 Gene inactivation GalT GalT-KO pig heart Baboon No improvement in coagulation problems in the GalT-KO context Ezzelarab et al.
5
Gene inactivation GalT PBMC from WT vs GalT-KO pig
Healthy human vs patients awaiting renal transplantation
Allosensitized compared to unsensitized patients at no greater risk of humoral rejection to pig xenografts Hara et al. The P8 sites associated with enhancer activity contained in pig ICAM-2 promoters seem to be crucial for achieving strong endothelial-specific transgene expression Godwin et al.
14
Genetic engineering in xenotransplantation S Le Bas-Bernardet et al Abbreviations: aGal, Gala1,3Galb1,4GlcNAc-R epitope; Ab, antibodies; BM, bone marrow; BMT, bone marrow transplantation; CDC, complement-dependent cytotoxicity; EndoGalC, endo-b-galactosidase C; GalT, a1,3-galactosyltransferase; GalT-KO, a1,3-galactosyltransferase knockout; GnT-I, N-acetylglucosaminyltransferase I; HAR, hyperacute rejection; hCRP, human complement regulatory proteins; hDAF, decay-accelerating factor or hCD55; HLA-E, human leukocyte antigen-E; hMCP, human membrane cofactor protein or hCD46; HT, a1,2-fucosyltransferase; iGb3S, isoglobotriaosylceramide-3 synthase; PBMC, peripheral blood mononuclear cell; PD-L1,programmed death ligand-1; pECs, porcine endothelial cells; PERV, porcine endogenous retrovirus; PIEC, porcine iliac endothelial cells; RBC, red blood cell; SCNT, somatic cell nuclear transfer; sCR1, soluble complement receptor-1; SCT, single-chain trimer; SMGT, sperm-mediated gene transfer; XNAs, natural xenoantibodies.
Immunological and biological barriers in xenotransplantation
The biggest hurdle in xenotransplantation is humoral rejection. This rejection exists in two forms. The first, called hyperacute rejection (HAR), is a very rapid phenomenon occurring within minutes to hours. The second occurs within weeks to months and is referred to as delayed xenograft rejection (DXR). Although both rejections display specific characteristics, both result from the binding of natural xenoantibodies (XNAs) to Gala1,3Galb1,4GlcNAc-R epitopes (aGal) present on the donor endothelium (reviewed in Yang and Zhong 23 ). Such binding results in uncontrolled complement activation, leading to complement-dependent cytotoxicity (CDC), endothelial damage, tissue edema, hemorrhage, fibrin deposition and microvascular thrombosis (Figure 1 ). aGal is expressed by all mammals except humans and Old World NHP. aGal is synthesized by a1,3-galactosyltransferase (GalT), which is not functional in humans and Old World NHP. The latter have therefore developed anti-aGal XNA.
Microvascular thrombosis is recognized as a critical element of humoral rejection and remains the major barrier to long-term pig-to-primate xenograft survival (survivals vary from a few weeks to 6 months for the longest one published) (reviewed in Cowan 24 ). Furthermore, incompatibility between pig thrombomodulin (TM) and primate thrombin could be involved in microvascular thrombosis during xenograft rejection. Roussel et al. 25 recently showed in vitro that pig TM bound to human thrombin inhibits its procoagulant activity but is a poor cofactor for human protein C activation (APC) and thrombin-activated fibrinolysis inhibitor, which interacts with various cofactors to shut down coagulation.
In addition to this early humoral involvement, cellular responses could also participate in xenogeneic rejection. Among the cells that contribute to the innate immune responses, human natural killer (NK) cells can adhere to and lyse porcine target cells both directly and indirectly with xenoreactive antibody (Ab) by Ab-dependent cellmediated cytotoxicity (ADCC) (reviewed in Kitchens et al. 26 ). Moreover, NK cell activity seems to be increased owing to the absence of self-MHC-mediated inhibitory signals and preserved interactions between the activator NKG2D receptor and ligands on porcine cells. 27 Macrophages also seem to play a role in the cellular response in non-vascular xenografts by developing a rapid, local innate response and stimulating the recruitment of T cells that act as direct effectors of rejection. The role of adaptive T-cell responses has been shown by the prolongation of xenograft survival after conventional immunosuppression and gene therapy protocols (reviewed in Pierson 28 ). Another major issue in xenotransplantation is the risk of virus infection, especially by porcine endogenous retrovirus (PERV). PERVs are integrated into the porcine genome and can be released as infectious particles from normal pig cells that could potentially infect human cells after transplantation. PERV-A and -B can infect human cells in vitro as well as immunodeficient mice transplanted with pig islets. Until now, no PERV transmission has been reported either in humans (more than 160 patients referred for direct contact with pig tissue in a 1999 retrospective study) or in NHP after xenotransplantation of porcine tissues, but no long-term studies in patients under immunosuppression have been reported (reviewed in Sprangers 29 ). Thus, the risk remains and deletion or knockdown of PERV sequences could be a solution.
Genetic engineering approaches leading to a reduction of aGal expression in donor cells/organs and production of a1,3-galactosyltransferase knockout pigs
One of the strategies to prevent HAR in xenotransplantation is the production of pigs no longer expressing the major xenoantigen aGal. This major step toward a potential clinical application was achieved in the last few years by generating pigs in which the two GalT genes have been invalidated. Thus, in the last few years, transplantations of hearts and kidneys from homozygous GalT knockout (GalT-KO) pigs to NHP have been performed with additional immunosuppression. Although GalT-KO organs are not hyperacutely rejected, powerful immunosuppressive regimens significantly higher than those used in clinical transplantation are needed to reach survivals over a few weeks. In all cases, HAR was prevented in control non-immunosuppressed animals, and variable prolongations of organ survival of up to 179 days for hearts and 83 days for kidneys have been reported (reviewed in 30 Cooper et al. and 31 Tai et al.). In another study in which a weaker immunosuppressive regimen was administered, kidney graft rejection occurred more rapidly between 8 and 16 days. This was due to an elicited anti-non-aGal humoral response Figure 1 (a) Mechanisms of vascularized xenograft rejection: (1) preformed natural xenoantibodies (XNAs) bind to aGal leading to the formation of the membrane attack complex (C 5À9 ), complement-dependent cytotoxicity (CDC) and then hyperacute rejection (HAR); (2) elicited XNAs bind to aGal and non-aGal epitopes leading to both CDC and antibody-dependent cell-mediated cytotoxicity (ADCC) and finally to delayed xenograft rejection (DXR); (3) increase in P-selectin, endothelial retraction, subendothelial matrix exposure: plasminogen activator inhibitor (PAI), factor VII (FVII), vonWillebrant factor (vWF), glycoprotein IB (gpIB), tissue factor (TF), platelet coagulation leading to coagulation and finally to DXR, possibly accompanied by disseminated intravascular coagulation (DIC); (4) cellular immune response involving cytotoxic T lymphocytes (CTLs), cytokine release, natural killer (NK) cells and leukocyte infiltration leading to direct cell lysis. (b) Genetic engineering strategies to prevent vascularized xenograft rejection: (1) knockout of the GalT gene leading to loss of aGal expression: absence of preformed XNA binding with aGal enabling the prevention of HAR, however, elicited anti-non-aGal antibody (Ab) persist or emerge inducing both CDC and ADCC leading to DXR; (2) complement blockade by human complement regulatory proteins (hCRPs): hCD46, hCD55, hCD59, hsCR1; absence of membrane attack complex formation and decrease of XNA-induced CDC; (3) expression of thromboregulatory molecules such as hCD39 leading to a decrease in thrombosis and DIC; (4) expression of protective molecules such as CTLA4Ig and HLA-E by graft endothelium, thereby reducing the cellular response: CTLA4Ig blocks the CD28:B7 costimulation signal leading to T-cell anergy in vitro: no cell proliferation and a decrease in cytokine production; HLA-E binding with CD94/NKG2A receptor-bearing NK cells inhibits direct NK cytotoxicity against the endothelium and subsequently decreases cellular rejection. Genetic engineering in xenotransplantation S Le Bas-Bernardet et al decrease (from 40% in the pancreas to 90% in the heart, kidney and lung) but not the disappearance of the aGal epitope. 1 Although the generation of EndoGalC transgenic animals seems to be a suitable approach in xenotransplantation, systemic EndoGalC expression in mice leads to early death, which may be resolved by using endothelial cell-specific promoters. With a similar strategy of reducing the antigenicity of pig tissues, Matsunami et al.
2 isolated the pig N-acetylglucosaminyltransferase I (GnT-I) gene coding for the enzyme that initiates the biosynthesis of hybrid-and complex-type N-glycans. After having constructed a point-mutated GnT-I gene, pigGnT-I(123) and pigGnT-I(320) constructs were introduced into normal porcine endothelial cells (pECs) to identify which GnT-I gene mutation was able to significantly alter the antigenicity of the N-linked sugars with respect to human sera. Expression of pigGnT-I(320) in pECs resulted in downregulation of aGal levels and a 30-40% decrease of CDC mediated by human xenoantibodies, suggesting that it is possible to remodel the carbohydrate structures within pig cells to alter their antigenicity.
A second strategy to control aGal expression is to delete or inactivate the GalT gene. It has been reported that rats have two functional GalT: the ortholog of GalT and the isoglobotriaosylceramide-3 synthase (iGb3S). Thus, there is a possibility that iGb3S may also be present in other species and may therefore account for the residual aGal expression in GalT-KO animals.
3 Along these lines, low levels of iGb3S mRNA have been detected both in the GalT-KO mouse and the pig thymus and lung, as well as in pECs. The results of immunization of GalT-KO mice with cells transfected with iGb3S, in comparison to GalT, suggest that aGal synthesized by iGb3S is as immunogenic as GalT. The recent description of mice deficient for iGb3S 32 will enable further testing to determine whether this finding could have an important impact on humoral-mediated rejection, such as DXR of GalT-KO organs.
To determine the most efficient and safe way to produce GalT À/À pigs, Nottle et al. 4 compared somatic cell nuclear transfer (SCNT) and breeding. In the breeding strategy, heterozygous GalT +/À -KO females were successively bred twice with wild-type male pigs to obtain homozygous GalT-KO animals. The results showed that GalT gene inactivation did not influence survival in utero and the GalT-KO crossbred pigs produced normal-size litters, suggesting that aGal may not be essential for normal pig reproduction. In the SCNT strategy, primary cultures of fetal fibroblasts were established from 25-day-old homozygous GalT-KO fetuses obtained by breeding one male and one female GalT +/À pig. After cell fusion of nuclei from homozygous GalT-KO fetuses with enucleated pig oocytes, SCNT GalT À/À embryos were transferred into five synchronized recipient females. Only one became pregnant and had a litter of four viable GalT À/À piglets. These results show that although less efficient than breeding, SNCT is also suitable for GalT À/À pig production. Moreover, the two techniques appear to be complementary in that breeding minimizes any inbreeding problems, whereas SCNT allows for an easier and more rapid introduction of multiple transgenes.
Even though it was shown that HAR was not observed in the context of GalT À/À donors, DXR occurred in baboon recipients of GalT-KO pig kidneys. This rejection was associated with complement activation and coagulation disorders, such as thrombotic microangiopathy and disseminated intravascular coagulation (DIC). To characterize better these two disorders and to assess the magnitude of abnormalities in the clotting system after xenotransplantation, Ezzelarab et al. 5 investigated the coagulation profile in baboons receiving GalT-KO pig hearts, compared to healthy baboons. Analyses of the coagulation profile revealed a similarity between healthy baboons and humans. Humoral rejection was observed in heparin-treated transplanted animals between days 8 and 12, with a clinical profile showing evidence of DIC (albeit not detectable in all historical series). As DIC as a consequence of non-Gal Ab-induced activation of endothelial cells may occur even with GalT-KO organs, the control of coagulation remains an important issue.
With the aim of moving xenotransplantation toward a clinical phase, Hara et al. 6 investigated the in vitro reactivity (IgM/G binding) and cytotoxicity of sera from healthy individuals, as well as unsensitized and allosensitized patients awaiting kidney transplantation, to WT versus GalT-KO pig peripheral blood mononuclear cell (PBMC). The results showed a decrease in serum reactivity as well as in the frequency of reactive and cytotoxic sera, with a lower cytotoxicity against GalT-KO than to WT pig cells in all the three groups of patients. No correlation was found between panel-reactive antibodies directed to human leukocyte antigen (HLA) class I or class II and cytotoxicity to WT or GalT-KO peripheral blood mononuclear cell. Moreover, there were no significant differences between healthy, unsensitized and allosensitized sera cytotoxicity to WT peripheral blood mononuclear cell and GalT-KO peripheral blood mononuclear cell, respectively. Thus, it appears that allosensitized patients would not be at greater risk of rejecting a pig organ than unsensitized patients. Despite dramatic progress in invalidating aGal expression, other issues including antibody responses and complement activation 6 need to be studied further by different genetic manipulations.
Control of complement through the use of transgenic pigs for multiple complement regulatory proteins
One strategy to reduce humoral xenogeneic rejection (HAR and DXR) in heart or kidney pig-to-primate transplantation is the inhibition of complement activation. Over the past 10 years, several pig lines have been generated that are transgenic for human complement regulatory proteins (CRPs), such as CD35 (complement receptor type 1 (CR1)), CD46 (membrane cofactor protein (MCP)), CD55 (decay-accelerating factor (DAF)) and CD59. Although CR1, MCP and CD55 inhibit complement activation at the C3/C5 level, CD59 inhibits formation of the membrane attack complex C 5b-9 . Despite the existence of GalT-KO animals, some authors have further investigated the humoral response against aGal in a CRP transgenic context. Thus, Zahorsky-Reeves et al. 7 identified IgV H genes encoding XNA in cynomolgus monkey recipients of pig hearts transgenic for hDAF under a treatment of GAS914 Genetic engineering in xenotransplantation S Le Bas-Bernardet et al (soluble aGal-conjugate that depletes anti-aGal Ab) and various immunosuppressive agents. The authors showed that hDAF transgenic organs transplanted into monkeys induced the same increase in anti-aGal and -non-Gal IgM/G Ab. The genetic basis for this humoral response in the immunosuppressed monkeys that rejected their graft indicated that the XNAs were encoded by a restricted family of V H 3 genes, with the potential of being specifically targeted using directed anti-B-cell therapeutics.
Deppenmeier et al. 8 analyzed pathomorphological lesions in organs and tissues from hCD59 transgenic pigs compared to non-transgenic pigs. Transgenic pigs were generated by microinjection of foreign DNA into zygote pronuclei. Variable transgene expression levels among both animals and tissues/organs were observed despite the use of the ubiquitously active cytomegalovirus promoter. The authors did not detect any specific pathological phenotype in pigs that could be associated with expression of the hCD59 transgene construct, leading them to conclude that this technology is suitable for biomedical applications.
In pulmonary xenotransplantation, complement inhibition by CRPs seems to be insufficient. Pö ling et al. 9 used an ex vivo perfusion model with fresh human blood to investigate the potential of hCD55 or hCD59 transgenic lungs to prevent pulmonary dysfunction and HAR. The results showed a partial protection from pulmonary dysfunction with hCD55 transgenic pig lungs, even though the typical histopathological features of HAR were still detectable. In the same model, no significant improvement was observed in lungs expressing hCD59 compared to non-transgenic lungs.
Wu et al. 10 studied the role of coagulation cascade activation in the pathogenesis of HAR and early graft failure in baboons transplanted with pig hearts transgenic for hDAF or hMCP. They concluded that dysregulated coagulation correlated closely with and probably caused primary failure of pig hearts transgenic for hCRP. Liu et al.
11 examined in vitro the relationship between the level of hDAF expression and its inhibitory effect on human serum cytotoxicity. A pCAGGS (plasmid) expression vector containing the cytomegalovirus enhancer, the chicken b-actin promoter and the hDAF gene was transfected into pig fibroblasts. The results suggested that a much higher expression of hDAF might be beneficial in protecting pig organs from the humoral xenogeneic response.
Smolenski et al. 12 evaluated the ability of hearts from hDAF transgenic pigs generated by sperm-mediated gene transfer (SMTG ¼ minigene introduction into sperm cells followed by artificial insemination) to protect from structural damage, metabolic changes and mechanical dysfunction during ex vivo perfusion with fresh human blood. In this context, the hearts were relatively stable metabolically and protected from HAR. Therefore, SMGT also seems to be suitable for the generation of genetically engineered donors for preclinical xenotransplantation.
Manzi et al. 13 showed in vitro that pECs transfected with a truncated form of human soluble CR1 (sCR1) were protected from CDC induced by human AB serum, suggesting that generating pigs expressing sCR1 could constitute an additional strategy to prevent HAR. The use of transgenic donors, specifically pigs, in xenotransplantation requires targeting of transgenes to produce transgenic donors with a strong and specific endothelial expression. With this aim in mind, Godwin et al.
14 characterized the pig ICAM-2 promoter by sequencing. Although their results showed many similarities between human and pig ICAM-2 promoters, the P 8 intronic site detected, which is associated with enhancer activity in the pig gene, may be crucial to achieve strong endothelial-specific transgene expression.
Genetic engineering for molecules that control coagulation activation
In the same way as human islets exposed to human blood, exposure of porcine islets to primate blood triggers an instant blood-mediated inflammation reaction (IBMIR) characterized by platelet consumption and activation of the coagulation and complement systems. The thromboregulatory molecule CD39 is an ectonucleotidase that degrades the platelet agonist ATP. Dwyer et al. 15 isolated pancreatic islets from hCD39 transgenic mice, incubated them with human blood and analyzed their impact on IBMIR in comparison to WT islets. The results showed that expression of hCD39 on murine islets significantly delayed clotting in human blood.
Genetic engineering for molecules that modify the cellular xenogeneic immune response
Several studies have been conducted to analyze whether hematopoietic chimerism, achieved using recipient bone marrow (BM) expressing aGal through transduction with lentiviral vectors, was able to inhibit anti-aGal XNA responses and induce tolerance to xenografts in mice 16 or to inhibit anti-aGal XNA responses in rhesus monkeys. 17 Mitsuhashi et al. 16 used lentiviral transfer of the GalT gene to autologous BM from GalT-KO mice and then transplanted the BM cells into submyeloablative irradiated GalT-KO mice. Following BM transplantation, the mice were immunized with rabbit red blood cells and subsequently grafted with aGal+ mice hearts. Anti-aGal Abs were not produced in GalT-reconstituted mice, in contrast to anti-non-Gal xenoAb. Fischer-Lougheed et al. 17 reproduced these results in rhesus macaques: several months post-BM transplantation, monkeys were immunized with porcine cells, and the anti-aGal IgM induction was considerably attenuated in aGal+BM recipients compared to immunized controls (no transplantation was performed at this stage). In these studies, the authors reported that this type of gene therapy approach was able to inhibit the production of anti-aGal Ab both in mice and in rhesus macaques, suggesting that B-cell tolerance achieved in mice could also be achieved in NHP.
To test the efficacy of local production of CTLA4-Ig in blocking the CD28:B7 costimulation pathway and more generally inhibiting xenogeneic T-cell responses, pECs were transduced with a lentiviral vector encoding CTLA4-Ig. 18 Murine splenocytes primed with pECs were used as responder cells in in vitro proliferation and cytokine assays against cells expressing or lacking Genetic engineering in xenotransplantation S Le Bas-Bernardet et al CTLA4-Ig compared to WT pECs. The results showed a significant inhibition of splenocyte proliferation (92%) and a marked reduction in interferon-g (82%), interleukin (IL)-4 (89%) and IL-10 (61%), suggesting the efficacy of such a strategy, even in the context of xenotransplantation.
Programmed death ligand-1 (PD-L1) is a B7 family molecule expressed by T cells, B cells, dendritic cells and macrophages. Programmed death-1 (PD-1), the physiological receptor of PD-L1, is expressed by activated T cells. Targeting of PD-1 signaling has been shown to promote allograft survival, and when combined with costimulatory blockade, it induced long-term allogenic islet graft survival. To evaluate the possible role of PD-1/PD-L1 interaction in pig-to-primate xenotransplantation, Jeon et al. 19 cloned porcine PD-L1 and characterized its function toward human CD4 T-cell proliferation stimulated by porcine PD-L1-transfected cells. In vitro functional analysis showed that porcine PD-L1 inhibited human xenogeneic CD4 T-cell proliferation, inducing T-cell apoptosis. The PD-1/PD-L1 pathway may therefore play a regulatory role in the host cellular immune response and improve graft survival in xenotransplantation.
It is hypothesized that pEC susceptibility to human NK-mediated lysis could be due to the inability of porcine MHC class I to signal through human NK cell inhibitory receptors. In this context, the non-classical HLA-E molecule is a potent activator of the inhibitory NK cell receptor CD94/NKG2A. To investigate whether pig organs expressing HLA-E could be protected in a xenogeneic context, Lilienfeld et al. 20 used the HLA-E single-chain trimer originating from linked sequences encoding for an HLA-E-binding peptide, the HLA-E a-chain and the human b2 microglobulin, to transfect porcine cells. Their results showed a significant decrease in polyclonal human NK-mediated cytotoxicity against pEC by the transgenic expression of HLA-E single-chain trimer. Furthermore, this HLA-E single-chain trimermediated protection was specifically reversed by blocking CD94/NKG2A. However, HLA-E expression affected neither the adhesion of human NK cells to pEC nor the heteroconjugate formation between human NK and porcine cells. Lilienfeld et al. 20 suggested that although insufficient to totally inhibit xenogeneic NK cell reactivity, transgenic HLA-E expression on pig organs might contribute to the success of clinical xenotransplantation in combination with other protective strategies.
Control of PERV expression in pig cells/organs by RNA interference
To attenuate the risk of PERV transmission in xenotransplantation, Dieckhoff et al. 21, 22 assessed the efficiency of RNA interference approach to inhibit expression of PERV in pigs. In an initial step, fetal pig fibroblasts were transduced with two different lentiviral vectors, RRL-PGK-GFP-pol2 and pLVTHM-pol2, which expressed short hairpin (sh)RNA corresponding to the viral pol2 sequence. They showed that transduction by both vectors induced an inhibition of PERV expression in fetal pig fibroblasts (B80%) that remained stable over months. 21 Subsequently, pigs transgenic for Pol2-shRNA were generated by SCNT, with the live-born piglets showing no malformations and a normal weight. 22 The transgene was present in all six piglets, and expression of pol2-shRNA was detected in all organs. PERV expression was significantly inhibited by up to 94% in all organs of two tested transgenic piglets, demonstrating the efficiency of the RNA interference approach in vivo. This strategy could clearly lead to safer porcine xenotransplants with regard to the PERV risk.
Prospects
The application of gene transfer and transgenic technologies to organ transplantation has already led to important breakthroughs in transplantation immunology and may have clinical applications in the future, both in the allotransplantation and in the xenotransplantation settings. Concerning aGal expression, even though GalT À/À pig organs were shown to be not susceptible to HAR in NHP models, these organs are still rejected at later time points by antibodies and complement activation. The targets of these antibodies are potentially other forms of Gal epitopes and a myriad of xenoantigens that generate induced antibodies. The deletion of the iGb3S gene 3, 33 or the expression of EndoGalC 1 in the GalT À/À background could result in further reduction in Gal epitope expression. As far as elicited anti-non-Gal Abs directed against non-Gal xenoantigens are concerned, the next major step is to generate genetically engineered pigs combining coexpression of different human genes (anticoagulant, CRP and/or molecules able to provide local immunosuppression) in the GalT-KO pig background. 4, 6, 12, 30, 33, 34 For example, during the last International Xenotransplantation Association Meeting, there were reports on the production of GalT-KO pigs coexpressing hCD39 35 and triple transgenic pigs expressing hCD55, hCD59 and hTM, 36 which should become very useful organ/cell donors for preclinical xenotransplantation studies. For xenotransplantation of pancreatic islets and neurons, it will be of interest to generate pigs genetically modified to express transgenes that control cellular xenogeneic immune responses, such as those expressing CTLA4-Ig by neurons. The final goal will be to control PERV expression in genetically engineered pigs to reduce the risk of host infection in the case of pig cell/organ xenotransplantations.
Regarding clinical studies, the international xenotransplantation community has so far put a non-official moratorium until the safety issue has been better clarified. However, future clinical trials using pig islets are seriously being considered and could probably be proposed soon.
Ethical considerations are of major importance in this field for many reasons. One of them is with regard to the rights of humans to use animals for medical purposes. Because of the genetic proximity of NHP with humans, the general consensus has been to ban their use in xenotransplantation (beyond the issue of viral risk). Besides, other issues such as informing the public, informed consents and so on, another ethical issue is related to the purpose of this article: Is it right for humans to modify the genetic background of another species?
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